SYRE Annual CFO
-$99.91 M
-$19.77 M-24.66%
31 December 2023
Summary:
As of January 21, 2025, SYRE annual cash flow from operations is -$99.91 million, with the most recent change of -$19.77 million (-24.66%) on December 31, 2023. During the last 3 years, it has fallen by -$24.14 million (-31.85%). SYRE annual CFO is now -1262.10% below its all-time high of -$7.33 million, reached on December 1, 2014.SYRE Cash From Operations Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
SYRE Quarterly CFO
-$29.42 M
+$32.83 M+52.74%
30 September 2024
Summary:
As of January 21, 2025, SYRE quarterly cash flow from operations is -$29.42 million, with the most recent change of +$32.83 million (+52.74%) on September 30, 2024. Over the past year, it has increased by +$5.18 million (+14.96%). SYRE quarterly CFO is now -1513.11% below its all-time high of $2.08 million, reached on June 1, 2021.SYRE Quarterly CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
SYRE TTM CFO
-$151.25 M
+$5.18 M+3.31%
30 September 2024
Summary:
As of January 21, 2025, SYRE TTM cash flow from operations is -$151.25 million, with the most recent change of +$5.18 million (+3.31%) on September 30, 2024. Over the past year, it has dropped by -$64.23 million (-73.82%). SYRE TTM CFO is now -11178.67% below its all-time high of -$1.34 million, reached on March 1, 2014.SYRE TTM CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
SYRE Cash From Operations Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -24.7% | +15.0% | -73.8% |
| 3 y3 years | -31.9% | -95.3% | -86.1% |
| 5 y5 years | -210.3% | -95.3% | -86.1% |
SYRE Cash From Operations High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -86.0% | at low | -95.3% | +52.7% | -181.6% | +3.3% |
| 5 y | 5-year | -86.0% | at low | -1513.1% | +52.7% | -193.2% | +3.3% |
| alltime | all time | -1262.1% | at low | -1513.1% | +52.7% | <-9999.0% | +3.3% |
Spyre Therapeutics Cash From Operations History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | -$29.42 M(-52.7%) | -$151.25 M(-3.3%) |
| June 2024 | - | -$62.25 M(+118.1%) | -$156.42 M(+41.2%) |
| Mar 2024 | - | -$28.54 M(-8.0%) | -$110.82 M(+10.9%) |
| Dec 2023 | -$99.91 M(+24.7%) | -$31.04 M(-10.3%) | -$99.91 M(+14.8%) |
| Sept 2023 | - | -$34.60 M(+107.9%) | -$87.01 M(+28.9%) |
| June 2023 | - | -$16.64 M(-5.6%) | -$67.48 M(-5.6%) |
| Mar 2023 | - | -$17.63 M(-2.8%) | -$71.52 M(-10.8%) |
| Dec 2022 | -$80.14 M(+49.2%) | - | - |
| Dec 2022 | - | -$18.14 M(+20.4%) | -$80.14 M(-1.4%) |
| Sept 2022 | - | -$15.07 M(-27.1%) | -$81.27 M(-2.3%) |
| June 2022 | - | -$20.67 M(-21.3%) | -$83.20 M(+37.6%) |
| Mar 2022 | - | -$26.26 M(+36.3%) | -$60.45 M(+12.5%) |
| Dec 2021 | -$53.72 M(-29.1%) | -$19.27 M(+13.3%) | -$53.72 M(+4.1%) |
| Sept 2021 | - | -$17.00 M(-916.5%) | -$51.58 M(-1.0%) |
| June 2021 | - | $2.08 M(-110.7%) | -$52.12 M(-29.2%) |
| Mar 2021 | - | -$19.53 M(+14.0%) | -$73.61 M(-2.9%) |
| Dec 2020 | -$75.78 M(+15.3%) | -$17.13 M(-2.3%) | -$75.78 M(+1.1%) |
| Sept 2020 | - | -$17.54 M(-9.7%) | -$74.94 M(+0.4%) |
| June 2020 | - | -$19.41 M(-10.5%) | -$74.61 M(+4.2%) |
| Mar 2020 | - | -$21.69 M(+33.1%) | -$71.58 M(+9.0%) |
| Dec 2019 | -$65.69 M | -$16.29 M(-5.3%) | -$65.69 M(+16.1%) |
| Sept 2019 | - | -$17.21 M(+5.0%) | -$56.60 M(+18.2%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| June 2019 | - | -$16.38 M(+3.6%) | -$47.89 M(+18.1%) |
| Mar 2019 | - | -$15.81 M(+119.5%) | -$40.55 M(+26.0%) |
| Dec 2018 | -$32.19 M(+30.8%) | -$7.20 M(-15.3%) | -$32.19 M(+4.3%) |
| Sept 2018 | - | -$8.50 M(-6.0%) | -$30.87 M(+3.8%) |
| June 2018 | - | -$9.04 M(+21.4%) | -$29.73 M(+11.6%) |
| Mar 2018 | - | -$7.45 M(+26.8%) | -$26.63 M(+8.2%) |
| Dec 2017 | -$24.61 M(+30.7%) | -$5.87 M(-20.3%) | -$24.61 M(+6.6%) |
| Sept 2017 | - | -$7.37 M(+24.0%) | -$23.10 M(+7.0%) |
| June 2017 | - | -$5.94 M(+9.4%) | -$21.59 M(+6.5%) |
| Mar 2017 | - | -$5.43 M(+24.7%) | -$20.28 M(+7.7%) |
| Dec 2016 | -$18.84 M(+71.6%) | -$4.36 M(-25.7%) | -$18.84 M(+23.0%) |
| Sept 2016 | - | -$5.87 M(+26.6%) | -$15.32 M(+15.5%) |
| June 2016 | - | -$4.63 M(+16.1%) | -$13.26 M(+6.2%) |
| Mar 2016 | - | -$3.99 M(+378.8%) | -$12.49 M(+13.7%) |
| Dec 2015 | -$10.98 M(+49.7%) | -$833.00 K(-78.1%) | -$10.98 M(-16.3%) |
| Sept 2015 | - | -$3.81 M(-1.1%) | -$13.12 M(+18.1%) |
| June 2015 | - | -$3.85 M(+55.3%) | -$11.12 M(+31.1%) |
| Mar 2015 | - | -$2.48 M(-16.5%) | -$8.48 M(+15.6%) |
| Dec 2014 | -$7.33 M | -$2.98 M(+65.1%) | -$7.33 M(+68.2%) |
| Sept 2014 | - | -$1.80 M(+48.1%) | -$4.36 M(+70.4%) |
| June 2014 | - | -$1.22 M(-9.2%) | -$2.56 M(+90.8%) |
| Mar 2014 | - | -$1.34 M | -$1.34 M |
FAQ
- What is Spyre Therapeutics annual cash flow from operations?
- What is the all time high annual CFO for Spyre Therapeutics?
- What is Spyre Therapeutics annual CFO year-on-year change?
- What is Spyre Therapeutics quarterly cash flow from operations?
- What is the all time high quarterly CFO for Spyre Therapeutics?
- What is Spyre Therapeutics quarterly CFO year-on-year change?
- What is Spyre Therapeutics TTM cash flow from operations?
- What is the all time high TTM CFO for Spyre Therapeutics?
- What is Spyre Therapeutics TTM CFO year-on-year change?
What is Spyre Therapeutics annual cash flow from operations?
The current annual CFO of SYRE is -$99.91 M
What is the all time high annual CFO for Spyre Therapeutics?
Spyre Therapeutics all-time high annual cash flow from operations is -$7.33 M
What is Spyre Therapeutics annual CFO year-on-year change?
Over the past year, SYRE annual cash flow from operations has changed by -$19.77 M (-24.66%)
What is Spyre Therapeutics quarterly cash flow from operations?
The current quarterly CFO of SYRE is -$29.42 M
What is the all time high quarterly CFO for Spyre Therapeutics?
Spyre Therapeutics all-time high quarterly cash flow from operations is $2.08 M
What is Spyre Therapeutics quarterly CFO year-on-year change?
Over the past year, SYRE quarterly cash flow from operations has changed by +$5.18 M (+14.96%)
What is Spyre Therapeutics TTM cash flow from operations?
The current TTM CFO of SYRE is -$151.25 M
What is the all time high TTM CFO for Spyre Therapeutics?
Spyre Therapeutics all-time high TTM cash flow from operations is -$1.34 M
What is Spyre Therapeutics TTM CFO year-on-year change?
Over the past year, SYRE TTM cash flow from operations has changed by -$64.23 M (-73.82%)